GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Structure Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$22.01+0.93 (+4.41%)
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.37 (−19.61%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $4.80B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.54
- Dividend yield
- –
- Free cash flow yield
- -4.68%
Fundamentals
- Net income
- -$214.84M
- EPS, diluted
- -$1.04
- Free cash flow
- -$224.50M
- Book value per share
- $6.21
- Diluted shares
- 218M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$257.81M
Net income
-$214.84M
EPS, diluted
-$1.04
Free cash flow
-$224.50M
Reported periodTrailing twelve months